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ABSTRACT 
OQective: Infection by antibiotic-resistant bacteria can pose 
serious complications to the therapy of cancer patients. The 
authors introduced DNA fingerprinting techniques for tracking 
methicillin-resistant Staphylococcus aureus (MRSA) clones 
recovered at a central cancer hospital of Lisbon (Instituto Por- 
tug&s de Oncologia) with the purpose of making an inventory 
of the MRSA clones endemic during 1995, and compared them 
with the outbreak-related clones of 1993. 
Design: A small group (6 strains) of epidemiologically related 
MRSA isolated during a suspected outbreak in 1993 and all 
consecutive single-patient isolates of MRSA (34 strains) recov- 
ered between January and November of 1995 from infected 
patients and health care personnel were characterized using 
DNA probes and pulsed-field gel electrophoresis. 
Results: The six 1993 strains and more than half of all 1995 iso- 
lates, including those recovered from the health care person- 
nel, showed DNA fingerprints characteristic of the “lberian 
MRSA,” a multiresistant clone widespread in Portuguese and 
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Spanish hospitals. Four patients were infected by another 
MRSA clone previously seen only in hospitals in Brazil. 
Conc/usion: The epidemic lberian clone was among the index 
cases involved with the MRSA outbreak in 1993, and this was 
found to be endemic in a follow-up survey conducted in 1995, 
colonizing health care personnel and spreading to most hos- 
pital wards. A few isolates of another epidemic clone, the Brazil- 
ian MRSA, also were detected among 1995 isolates. A better 
understanding of the mechanism(s) of epidemicity of these 
rapidly spreading clones is urgently needed. 
Key Words: methicillin-resistant Staphylococcus aureus, 
molecular epidemiology; molecular typing, 
MRSA clones, MRSA outbreak, oncology 
Int J Infect Dis 1998; 3:26-31. 
Infection by antibiotic-resistant strains of staphylococci 
presents a particularly serious and potentially life-threat- 
ening complication in cancer patients with prolonged 
hospitalization and frequent need of invasive procedures 
in the therapy of the primary disease. In Portugal, the 
first report of an epidemic spread of methicillin-resistant 
Staphylococcus aureus (MRSA) in a hospital unit 
occurred in 1984. l Currently, the frequency of this multi- 
resistant pathogen in Portuguese hospitals is high, reach- 
ing an average of 47% MRSA, according to a survey of 10 
hospitals.* In 1992, the laboratory of Molecular Genetics 
began a series of collaborative studies with Portuguese 
hospitals to assist in typing MRSA isolates by techniques 
of molecular epidemiology.3-7 A temporal scheme has 
been developed for the evolution of the clonal profile of 
MRSA in the participating Portuguese hospitals, and the 
regional spread of the epidemic clones has been moni- 
tored. Since 1995, this laboratory has become a center of 
molecular epidemiologic investigations (the CEM/NET 
Initiative),s observing the geographic expansion of epi- 
demic clones through several countries in Europe, South 
America, Asia, and United States. 
In the study presented here, these techniques were 
used to identify MRSA strains that were involved in a 
1993 hospital outbreak and to provide clonal profiles of 
MRSA resident in the Instituto Portugu& de Oncologia 
during a survey conducted in 1995. 
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MATERIAL AND METHODS 
Hospital 
Instituto Portugu@s de Oncologia de Francisco Gentil is 
the central cancer hospital of Lisbon, providing special- 
ized care for patients suffering from neoplastic diseases. 
It has 500 beds distributed among ten surgical units: three 
of medicine, three of general surgery, one of pediatrics, 
one intensive care unit (ICU), and two units of bone mar- 
row transplantation. 
The percentage of MRSA isolates in this hospital was 
31.3% during 1993 and 24.9% during 1995. These 
frequencies were based on the total number of S. aureus 
isolates present in samples sent by all units to the bac- 
teriology laboratory. 
In the beginning of October of 1993, personnel in the 
bacteriology laboratory became concerned about an 
apparent outbreak of MRSA, as evidenced by the simul- 
taneous isolation of three MRSA strains from purulent 
exudates of three postoperative patients from the same 
surgical unit (designated CIII). 
Methicillin-Resistant Staphylococcus 
aweus Isolates 
Forty MRSA clinical isolates (designated by the code IPO) 
were analyzed in this work (Table 1). These isolates 
Table 1. Phenotypic Properties of the Forty Methicillin-Resistant Stapby/ococcus aureus (MRSA) 
Recovered in 1993 and 1995 at lnstituto Portugu& de Oncologia de Francisco Gent& Lisbon, Portugal 
Clonal Type Patient(P) Resistant to 
(mecA:: Strain and a Pane/ of Me thicillin 
Tn554*:: Isolates Code isolation Origin of Service Nurse (N) Sex Age 14 Antibiotics* (7 mg/disk) 
PFGE) (n = 40) (/PO) Date /so/ate Code+ Code (n/l/F) (Y Except: (mm) Spc§ 
I::E::A2 4 
I::E::A3 1 
I::E::A4 1 
I::E::A5 1 
l::E::A6 6 
I::E::A8 9 
I::E::AI 1 1 
I::DD::Al 1 
I::DD::A12 3 
I::+::AlO 1 
I::NH::A7 1 
XIII::E::A9 1 
XI::B::BI 3 
XI::B::B2 1 
XI::lI::C 1 
II::NH::D 3 
I::E::E 2 
2 
6 
93 
5 
22 
61 
49 
68 
70A 
97 
110 
111 
59 
84 
86 
87 
88 
89 
90 
99 
104 
77 
4 
23 
33A 
53 
3 
73 
108 95.11.07 
25 95.02.04 
38 95.02.25 
69 95.07.31 
45 95.03.21 
54 95.04.26 
58 95.05.17 
66 95.06.06 
92 95.09.23 
30 95.02.14 
106 95.11.02 
93.10.07 
93.10.06 
93.11.04 
95.09.24 
93.10.26 
95.01.28 
95.05.19 
95.03.31 
95.06.14 
95.08.07 
95.10.06 
95.11.09 
95.11.10 
95.05.18 
95.08.31 
95.09.02 
95.09.05 
95.09.13 
95.09.13 
95.09.14 
95.10.13 
95.10.27 
95.08.11 
93.10.18 
95.01.31 
95.02.17 
95.04.22 
93.10.07 
95.08.09 
Drainage (liquid thorax) 
Pus (abdominal cavitv) 
Pus (surgical wound) 
Hemoculture 
Nasal swab 
Sputum 
Pus 
Hemoculture 
Hemoculture 
Catheter 
;;;fistula) 
Pus (fistula) 
Pus (surgical wound) 
Pus 
Nasal swab 
Nasal swab 
Nasal swab 
Nasal swab 
Nasal swab 
Pus 
Pus 
Pus (surgical wound) 
Catheter tip 
Pus (surgical wound) 
Hemoculture 
Pus (surgical wound) 
Pus (surgical wound) 
Hemoculture 
Exudate 
Pus (surgical wound) 
Catheter 
Pus 
Catheter tip 
Peritoneal fluid 
Nasal swab 
Hemoculture 
Pus 
Pus (surgical wound) 
Pus (trachaeostomy) 
Clll 
Clll 
Clll 
CVI 
Clll 
CVII 
Clll 
CVII 
CVI 
ICU 
CVI 
CVII 
CVI 
CVIII 
CII 
CII 
CII 
CII 
CII 
CII 
CII 
Clll 
Transf.CII 
amb.CIII 
WI 
amb.CIII 
Clll 
CVI 
CVI 
Cl 
CVII 
CVII 
CVII 
ICU 
ICU 
CVI 
amb.CII 
Cl 
Cl 
Pi M 
P2 M 
P5 M 
P27 M 
Nl F 
P7 M 
Pi8 M 
Pi4 M 
P20 M 
P22 M 
P28 M 
P34 F 
P31 F 
PI7 F 
P25 F 
N2 F 
N3 F 
N4 F 
N5 F 
N6 F 
P29 F 
P30 F 
P24 M 
P4 M 
P8 F 
PI1 F 
PI5 F 
P3 M 
P23 M 
P33 M 
P9 M 
Pi2 F 
P21 M 
Pi3 F 
P6 M 
P16 M 
Pi9 M 
P26 F 
PI0 M 
P32 M 
68 
66 
60 
67 
72 
63 
59 
54 
64 
66 
57 
47 
63 
36 
29 
23 
43 
22 
67 
85 
70 
66 
80 
33 
56 
67 
50 
- 
47 
36 
60 
54 
65 
SXT 16 
SXT 15 
SXT 15 
SXT 14 
SXT 17 
SXT 12 
SXT 14 
SXT 13 
SXT 12 
SXT 13 
SXT 1.5 
SXi- 13 
SXT 13 
SXT 11 
SXT 15 
SXT 13 
SXT 17 
SXT 14 
SXT 14 
SXT 13 
SXT 14 
SXi- 15 
SXT 14 
SXT 17 
SXT 14 
SXT 11 
SXT 12 
SXT 15 
SXr, E 16 
SXT 16 
None 13 
None 12 
None 15 
None 18 
AK,C 17 
- AK,C,CN,E,I,KF,SXT 29 
75 AK.C.CN,E.SXT 27 
62 AK,C,CN,i+XT 26 
55 SXT 11 
89 SXT 13 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
S 
R 
S 
S 
S 
S 
R 
S 
S 
S 
R 
R 
PFGE = pulsed-field gel electrophoresis; M = male: F = female; Spc = spectinomycin. 
*NH = absence of homology with the Tn554 transposon. 
+Six surgical services (Cl, CII, CIII, CVI, CVII, CVIII) and ICU. amb = ambulatory service (external patient); transf = transferred to, 
*amikacin (AK); cefalothin (KF); cefotaxime (CTX); cefoxitin (FOY); ciprofloxacin (C); erythromycin (E); gentamicin (CN); imipenem (I); methicillin; oxacillin; penicillin; 
sulfamethoxazole/trimethoprim (SW; all isolates were susceptible to teicoplanin and vancomycin. Kanamycin and perfloxacin were tested only in 1993, and all strains 
were resistant. Ceftriaxone was tested only in 1995, and all strains were resistant. 
5500 pg/mL; R = resistant: S = susceptible. 
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Figure 1. Stability of Tn554 insertion patterns E, IJJ, and DD. One isolate each carrying Tn554 
patterns E, DD, and $ was tested for the stability of its respective Tn554 type during extensive 
serial passage in drug-free medium in vitro. Single-colony isolates were inoculated into TSB and 
grown from small inocula (103 to 104 CFU/mL) to turbid cultures (1010 CFWmL), and such pas- 
sage was repeated in six consecutive cycles. At the end of each cycle of cultivation, the bacte- 
ria were tested for their Tn.554 pattern: chromosomal DNAs were restricted with C/al, separated 
by conventional gel electrophoresis, transferred to a nylon membrane, and hybridized with a 
Tn554specific probe (see Material and Methods). Lanes 1 and 24: 1 Kb DNA ladder, Gibco BRL, 
Life Technologies (BRL); lanes 2 and 3 are control strains, HSAl and RN1 61, respectively, C/al- 
Tn554 pattern E and C/al-Tn554 pattern U; lanes 4-9: six DNA samples of strain IPO2, C/al-Tn554 
pattern E; lanes 10-15: six DNA samples of strain IPO3, CWTn554 pattern @; lanes 16-21: six 
DNA samples of strain IPO4, C/al-Tn554 pattern DD; lanes 22 and 23 are control strains, RN1 389 
and BK950, respectively, C/al-Tn554 pattern E and C/al-Tn554 oattern DD. 
include: (i) six MRSA epidemiologically related to an out- 
break in surgical unit CIII in October and November 
19939: five isolates were recovered from five infected 
patients and one isolate was from a nasal swab of a nurse, 
the unique MRSA carrier identified after screening 117 
nasal swabs from health care personnel of surgical unit 
CIII as well as all people who might have had contact 
with the patients of unit CIII; (ii) 29 consecutive single- 
patient MRSA isolates recovered during the surveillance 
period between January and November of 1995; and 
(iii) MRSA identified in nasal swabs taken from five muses 
during the same surveillance period. 
Antimicrobial Susceptibility Testing 
All isolates were tested by disk diffusion methods against 
14 antimicrobials: amikacin (AK), cefalothin (KF), cefo- 
taxime (CTX), cefoxitin (FOX), ciprofloxacin (C), ery- 
thromycin Q, gentamicin (CN), imipenem (I), methicillin 
(M), oxacillin (0) penicillin G (P), teicoplanin (‘I), sul- 
famethoxazole/trimethoprim (SXT), vancomycin (V).” 
Methicillin resistance in the clinical laboratory was tested 
using both oxacillin disks (1 Fg) and methicillin disks 
(5 pg) in Mueller-Hinton media with 4% NaCl and incu- 
bation for 24 hours at 35°C and Mueller-Hinton media 
without salt and incubation for 24 to 48 hours at 30°C 
according to recommended methodologies.1° In the 
research laboratory the nature of the methicillin resis- 
tance phenotype (homogeneous or heterogeneous) also 
was tested for all isolates, by a disk diffusion method, 
with 1-mg/disk methicillinn Resistance to 500 kg/mL of 
spectinomycin was evaluated by spotting 5 p,L drops of 
overnight-grown cultures (109-lo CFU/mL) onto TSA 
plates containing that concentration of the antibiotic.‘* 
DNA Electrophoresis and 
Southern Blot Hybridization 
Preparation of chromosomal DNAs, endonuclease diges- 
tion with CZaI (Stratagene, La Jolla, CA) and SmaI (New 
England Biolabs, Beverly MA), conventional electrophore- 
sis, pulsed-field gel electrophoresis (PFGE), and Southern 
blot were performed as previously described.3,13 The DNA 
probes specific for the mecA gene, Tn554 transposon, and 
the mecRl-mec1 sequences were as described.3~1z~‘4-17 
Labelling of the probes and (pre) hybridization were car- 
ried out using the nonradioactive labelling system ECL 
(Amersham, Int., Buckinghamshire, UK), according to the 
manufacturer’s instructions. Purification of the restriction 
fragments was done using the USBioclean MP System 
(United States Biochemical Corporation, Cleveland, OH), 
according to the manufacturer’s recommendations. Ref- 
erence strains for the CZaI-mecA patterns, CZaI-Tn554 pat- 
terns, and representative strains used to compare the 
PFGE profiles were obtained from strain collections at 
The Rockefeller University and at the Instituto de Tec- 
nologia Quimica e Biologica (ITQB). 
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RESULTS AND DISCUSSION 
Characterization of MRSA Gem Instituto 
PortuguQ de Oncologia de Francisco Gentil 
by Molecular Fingerprinting Techniques 
The molecular fingerprinting methods used in this study 
consisted of the analysis of the mecA vicinity polymor- 
phisms, the Tn554 transposon insertion patterns and the 
SmaI macrorestricion profiles resolved by PFGE. 
The MRSA isolates analyzed in this study, six MRSA 
from 1993 and the 34 MRSA recovered during the 1995 
surveillance, are grouped according to clonal type and 
in the order of calendar date of isolation in Table 1. The 
strains from 1993 included five from patients and one 
from a nurse. The surveillance cultures included 29 con- 
secutive single-patient isolates and five MRSA recovered 
from nasal swabs of five nurses. 
The six isolates from 1993 showed a common mecA 
polymorph I in combination with four subtypes of PFGE 
pattern A and carried three Tn554 patterns. Twenty- 
three of the 34 single-patient isolates (68%) recovered 
during the 1995 surveillance period also carried the 
mecA polymorph I in combination with one of several 
subtypes of PFGE pattern A, and all but four of these iso- 
lates (i.e., 19/23) also shared a common Tn554 pattern 
E. Subtype variants of the same clonal type (I::E::A) also 
were identified from the nurses: variant 1::E::Ag from the 
five nurses in 1995, and I::E::A3 from the nurse in 1993. 
The MRSA clone 1::E::A was clearly the dominant 
one (23/40 isolates) during the entire period of 1993 
and 1995. Isolates belonging to this clonal type also 
shared common antibiotype (resistance to 11 of the 14 
antibiotics tested), and they also expressed a common, 
homogeneous, methicillin-resistant phenotype, indicated 
by the narrow inhibition zones around the 1-mg methi- 
cillin disk (see Table 1). In five of the mecA polymorph 
I and PFGE pattern A isolates from 1993 and 1995, the 
Tn554 pattern E was replaced by either pattern DD or 
Q or the transposon was lost (NH) (Figure 1). 
The 29 MRSA isolates representing these closely 
related clonal types (the 23 single-patient isolates and 
the 6 isolates carried by the nurses) were recovered in 
six different wards and the ICU of the hospital, indicat- 
ing a wide dispersal. Clonal assignments (six distinct 
clonal types), recovery dates, and in-hospital dispersal of 
the remaining 11 MRSA isolates are shown in Table 1. 
Table 2 summarizes the size of the SmaI-generated 
DNA fragments hybridizing with the DNA probes spe- 
cific for mecA, Tn554, and mecRl-mec1. The mecRl-mec1 
probe only hybridized with the DNAs of strains belong- 
ing to ClaI-mecA::Tn554 types XVI::(r and XI::B in sin- 
gle SmaI fragments of 184 and 120 Kb, respectively. 
Figure 2 shows a gel illustrating all the PFGE types and 
subtypes detected in this study. 
PFGE Subtypes and Variation in Tn554 Pattern 
It was shown repeatedly that the properties used for the 
clonal characterization of MRSA (such as mecA or Tn554 
polymorphism or PFGE pattern) remain unchanged dur- 
ing multiple passages in the laboratory through hundreds 
of generations of growth in antibiotic-free medium. There- 
fore, the appearance of PFGE subtype variants or changes 
in Tn554 pattern frequently observed among strains 
recovered from the clinical environment must reflect 
genetic events that occur in vivo. The mechanism of these 
changes is not well understood, neither are the in vivo 
operating factors invoking them. 
In the case of oncology patients undergoing radia- 
tion treatment or chemotherapy against the primary dis- 
ease, it is conceivable that such potentially mutagenic 
agents may contribute to the instability of clonal types. 
Two MRSA strains with identical mecA types and PFGE 
profiles but distinct Tn554 patterns were both isolated 
from patients who were exposed to such treatments. 
Strain IPO 3 (I::$::AlO) was recovered from patient 3 
who had rectal cancer and underwent radiotherapy for 
more than 1 month. Isolate IPO 4 (,I::DD::Al) was from 
patient 4 who had bladder cancer and underwent both 
chemotherapy and radiotherapy The other three MRSA 
strains (IPO 1, IPO 2, IPO 6 ) with identical mecA types, 
Tn554 patterns, and PFGE (I::E::A) isolates were respec- 
tively from patients 1, 2, and 6 who never underwent 
either chemotherapy or radiotherapy. 
Table 2. DNA Hybridization Patters of the Forty MRSA 
Strains Recovered at lnstituto Portuguk de Oncologia 
Smal- Hybridiza t/on 
Fragments 
Clonal Type (Kb, approx.) 
(me&: 
Tn554:: me&U- 
/PO Isolates* PFGE) mecA Tn554 mecl 
1,2,6,93 I::E::A2 203 646 NH 
5 I::E::A3 214 646 NH 
22 I::E::A4 214 744 NH 
61 I::E::A5 214 646 NH 
49,68,70A,97,1 IO,1 11 I::E::A6 214 646 NH 
59,84,86,87,88,89,90,99,104 I::E::A8 214 646 NH 
77 I::E::AI 1 214 646 NH 
4 I::DD::AI 214 646,422 NH 
23,33A,53 I::DD::A12 220 646,462 NH 
3 I::Jr::AlO 214 646,325 NH 
73 I::NH::A7 214 NH NH 
108 XIII::E::AS 214 646 NH 
25,38,69 XI::B::Bl 119 646,119,98 120 
45 XI::B::B2 119 646,119,98 120 
54 xvI::cL:C 197 646,186 184 
58,62,92 II::NH::D 197 NH NH 
30,106 I::E::E 220 646 NH 
*IPO strains l-6 were isolated in October-November 1993. The remaining 
isolates were recovered during January to November 1995. Isolates tested 
include both single-patient isolates (34 strains) and nasal swabs from health 
care personnel (6 strains, IP06 and IPO86-90). NH = absence of homology with 
the DNA probes (Tn554 transposon or mecR1 -mecl sequences). 
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The stability of both Tn554 insertion patterns 9 and 
DD as well as pattern E was confirmed in vitro. The 
results showed that these patterns were stable over a 
5-week period of serial passages in nonselective drug- 
free medium (see Figure 1). 
The Nature of the MRSA Outbreak Strains 
Strain IPO 1 was isolated on October 7, 1993, from the 
pleural fluid of patient 1, who had lung cancer. Strain 
IPO 2 was isolated on October 6 of the same year from 
patient 2, who had stomach carcinoma, and strain IPO 6 
was isolated on November 4, 1993, from patient 6 who 
had esophageal cancer. All three patients were in surgi- 
cal unit CIII, and the fingerprinting methods identified 
the invasive MRSA outbreak strains as representatives of 
a single multiresistant MRSA with the clonal type of 
I::E::A2, which is the clonal assignment of the Iberian 
clone of MRSA that was formerly shown to be widespread 
in Portuguese and Spanish hospitals.5-7~1s,17 
Clonal Profile of MRSA Endemic 
in IPO during the 1995 Surveillance 
Single PFGE subtype variants of the MRSA clone 1::E::A 
remained dominant in the cancer hospital during 1995, 
12345 6 7 0 9 10 11121314151617161920 
among both invasive and colonizing specimens. Among 
the six other clonal types of MRSA, each of which was 
represented by a few isolates, of some importance is the 
appearance of the MRSA clonal types XVI::o::C and 
II::NH::D, associated to both ambulatory and interned 
patients of ICU and one surgical unit. Clonal type 
XVI::a::C is a mecA variant of clone III::o::C, which was 
identified as responsible for infection and colonization 
of patients and nurses in 1985 in a burn unit of a pedi- 
atric hospital of Lisbon3 Since 1992, this clone was 
replaced in that hospital by two distinct clonal types: the 
Iberian clone and a clone defined as 1I::NH::D (S&Lea0 R, 
et al. Unpublished data), which has molecular properties 
similar to clonal type 1I::NH::D found in IPO represent- 
ing three strains recovered from patients 16, 19, and 26 
(see Table 1). Also of considerable importance is the 
appearance of the multiresistant MRSA clone XI::B::Bl, 
formerly only seen in Brazil where it is widespread in 
hospitals separated by vast geographic distances.20 The 
recovery of this clone from five patients hospitalized in 
two surgical wards of IPO, together with data obtained 
from studies conducted in the authors’ research labora- 
tory between 1992 and 1997, are evidence for the inter- 
continental transfer of this MRSA from South America to 
Europe. 
Figure 2. Pulsed-field gel electrophoresis (PFGE) of MRSA clinical isolates collected in 
October 1993 and during 1995 at lnstituto Portugues de Oncologia, Portugal. Chromosomal 
DNAs were digested with Smal endonuclease and the fragments were separated by PFGE (see 
Material and Methods). Lanes 1, 14, and 20: lambda ladder; lanes 2-13 and 15-19: PFGE of 
clinical isolates-lane 2, IP04 (PFGE pattern Al); lane 3, IP02 (PFGE pattern A2); lane 4, IPO5 
(PFGE pattern A3); lane 5, IPO22 (PFGE pattern A4); lane 6, IPO61 (PFGE pattern A5); lane 7, 
IPO68 (PFGE pattern A6); lane 8, IP073 (PFGE pattern A7); lane 9, IPO84 (PFGE pattern A8); 
lane IO, lPOlO8 (PFGE pattern AQ); lane 11, IP03 (PFGE pattern Al 0); lane 12, IP077 (PFGE 
pattern Al 1); lane 13, IP033A (PFGE pattern Al2); lane 15, IPO54 (PFGE pattern C); lane 16, 
IPO30 (PFGE pattern E); lane 17, IPO25 (PFGE pattern Bl); lane 18, IPO45 (PFGE pattern 92); 
lane 19, IPO66 (PFGE pattern D). 
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